To include your compound in the COVID-19 Resource Center, submit it here.

Quicker label for Stendra boosts Vivus

Vivus Inc. (NASDAQ:VVUS) gained $0.48 (12%) to $4.36 on Thursday after FDA approved

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE